

Floriana Morgillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6782352/publications.pdf>

Version: 2024-02-01

116
papers

6,074
citations

81743

39
h-index

74018

75
g-index

119
all docs

119
docs citations

119
times ranked

9919
citing authors

#	ARTICLE	IF	CITATIONS
1	Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103538.	2.0	13
2	Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 109.	3.5	7
3	Immunotherapy for head and neck cancer: Present and future. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103679.	2.0	45
4	A Trimodality, Four-Step Treatment including Chemotherapy, Pleurectomy/Decortication and Radiotherapy in Early-Stage Malignant Pleural Mesothelioma: A Single-Institution Retrospective Case Series Study. <i>Cancers</i> , 2022, 14, 142.	1.7	3
5	Gut microbiota correlates with antitumor activity in patients with <scp>mCRC</scp> and <scp>NSCLC</scp> treated with cetuximab plus avelumab. <i>International Journal of Cancer</i> , 2022, 151, 473-480.	2.3	24
6	Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1086-1097.	0.5	25
7	Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 15.	3.5	13
8	Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592094941.	1.4	35
9	Dual inhibition of TGF β 2 and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. <i>Medical Oncology</i> , 2021, 38, 24.	1.2	7
10	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. <i>Lung Cancer</i> , 2021, 152, 165-173.	0.9	23
11	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. <i>BMC Cancer</i> , 2021, 21, 549.	1.1	10
12	Hypothalamicâ€Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies. <i>Cancers</i> , 2021, 13, 4036.	1.7	3
13	PercuTwist tracheostomy in an intubated patient with tracheal stent. <i>Asian Cardiovascular and Thoracic Annals</i> , 2021, 29, 431-433.	0.2	0
14	Baseline IFN γ 3 and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. <i>Scientific Reports</i> , 2020, 10, 17626.	1.6	20
15	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 138, 1-10.	1.3	23
16	Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!. <i>Annals of Translational Medicine</i> , 2020, 8, 1199-1199.	0.7	0
17	Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer. <i>ESMO Open</i> , 2020, 5, e000753.	2.0	25
18	Metformin: An old drug against old age and associated morbidities. <i>Diabetes Research and Clinical Practice</i> , 2020, 160, 108025.	1.1	64

#	ARTICLE	IF	CITATIONS
19	Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania "Luigi Vanvitelli"™. <i>ESMO Open</i> , 2020, 5, e000675.	2.0	11
20	Efficacy and safety of immunotherapy in non-small cell lung cancer patients with poor performance status. <i>Journal of Clinical Oncology</i> , 2020, 38, e21601-e21601.	0.8	3
21	<p>Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 867-876.	1.0	8
22	Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. <i>Cancers</i> , 2019, 11, 1504.	1.7	36
23	Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma. <i>Thoracic Cancer</i> , 2019, 10, 2308-2311.	0.8	3
24	Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 41.	3.5	57
25	Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 253.	3.5	58
26	Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 236.	3.5	17
27	Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials. <i>Lung Cancer</i> , 2019, 133, 62-68.	0.9	5
28	Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 178.	3.5	28
29	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 845-855.	1.9	58
30	Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis. <i>Scientific Reports</i> , 2019, 9, 4986.	1.6	15
31	How I treat malignant pleural mesothelioma. <i>ESMO Open</i> , 2019, 4, e000669.	2.0	12
32	Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?. <i>Translational Cancer Research</i> , 2019, 8, S618-S620.	0.4	6
33	Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study. <i>ESMO Open</i> , 2019, 4, e000536.	2.0	26
34	ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer. <i>EBioMedicine</i> , 2019, 39, 5-6.	2.7	2
35	Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. <i>Journal of Thoracic Oncology</i> , 2018, 13, 810-820.	0.5	29
36	HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3595.	1.8	78

#	ARTICLE	IF	CITATIONS
37	Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives. <i>Frontiers in Endocrinology</i> , 2018, 9, 115.	1.5	26
38	Role and targeting of anaplastic lymphoma kinase in cancer. <i>Molecular Cancer</i> , 2018, 17, 30.	7.9	71
39	Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota. <i>Neoplasia</i> , 2018, 20, 721-733.	2.3	65
40	Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells. <i>Oncotarget</i> , 2018, 9, 19273-19282.	0.8	10
41	Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report. <i>Oncology Letters</i> , 2017, 13, 979-983.	0.8	0
42	Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. <i>Cancer Treatment Reviews</i> , 2017, 53, 61-69.	3.4	118
43	Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000132.	2.0	61
44	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. <i>ESMO Open</i> , 2017, 2, e000177.	2.0	27
45	Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7447-7458.	2.9	25
46	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. <i>World Journal of Gastroenterology</i> , 2017, 23, 4675.	1.4	91
47	Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. <i>Oncotarget</i> , 2017, 8, 82773-82783.	0.8	8
48	Phosphatidylinositol 3-kinase (PI3K)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. <i>Oncotarget</i> , 2017, 8, 76479-76491.	0.8	24
49	Implication of the Hedgehog pathway in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 4330.	1.4	54
50	Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. <i>Oncotarget</i> , 2017, 8, 23020-23032.	0.8	33
51	Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. <i>Oncotarget</i> , 2017, 8, 67592-67604.	0.8	15
52	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 68305-68316.	0.8	27
53	Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. <i>Oncotarget</i> , 2016, 7, 4265-4278.	0.8	58
54	Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review. <i>Oncology Letters</i> , 2016, 12, 4505-4509.	0.8	0

#	ARTICLE	IF	CITATIONS
55	BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 461-465.	1.1	37
56	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2016, 18, 59.	1.8	35
57	Mechanisms of resistance to EGFR-targeted drugs: lung cancer. <i>ESMO Open</i> , 2016, 1, e000060.	2.0	325
58	Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. <i>ESMO Open</i> , 2016, 1, e000088.	2.0	85
59	Therapies in the pipeline for small-cell lung cancer: Table 1. <i>British Medical Bulletin</i> , 2016, 119, 37-48.	2.7	11
60	Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1133-1141.	0.5	212
61	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. <i>Clinical Cancer Research</i> , 2015, 21, 4153-4164.	3.2	21
62	Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. <i>Clinical Cancer Research</i> , 2015, 21, 2975-2983.	3.2	63
63	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4686-4697.	3.2	103
64	A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. <i>Clinical Lung Cancer</i> , 2015, 16, 57-59.	1.1	16
65	AXL is an oncotarget in human colorectal cancer. <i>Oncotarget</i> , 2015, 6, 23281-23296.	0.8	55
66	Baseline neutrophil-lymphocyte ratio as a prognostic factor for patients with resectable gastric cancer undergoing adjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, e15018-e15018.	0.8	0
67	Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. <i>Annals of Translational Medicine</i> , 2015, 3, 81.	0.7	9
68	Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. <i>Biomedicines</i> , 2014, 2, 345-358.	1.4	30
69	Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 809-821.	1.9	29
70	Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2014, 15, 173-181.	1.1	56
71	Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. <i>Clinical Cancer Research</i> , 2014, 20, 3775-3786.	3.2	89
72	Incidence and prognostic significance of HER2 overexpression in gastric cancer (GC): A monoinstitutional retrospective analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 160-160.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Postoperative chemoradiation FOLFOX 4-based for R1 resected gastric cancer: A retrospective mono-institutional study.. Journal of Clinical Oncology, 2014, 32, 143-143.	0.8	0
74	Combination nab-paclitaxel (Nab-P) plus gemcitabine (G) as first-line treatment in advanced pancreatic cancer (APC): Our experience.. Journal of Clinical Oncology, 2014, 32, e15257-e15257.	0.8	0
75	Metformin in lung cancer: rationale for a combination therapy. Expert Opinion on Investigational Drugs, 2013, 22, 1401-1409.	1.9	23
76	Delivery optimization of erlotinib according to toxicity: May clinical practice go beyond research?. Lung Cancer, 2013, 80, 352-353.	0.9	0
77	Emerging VEGF-receptor inhibitors for colorectal cancer. Expert Opinion on Emerging Drugs, 2013, 18, 25-37.	1.0	26
78	Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. International Journal of Cancer, 2013, 133, 2089-2101.	2.3	81
79	Increased TGF- β as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells. Clinical Cancer Research, 2013, 19, 6751-6765.	3.2	130
80	Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?. Therapeutic Advances in Medical Oncology, 2013, 5, 51-72.	1.4	11
81	The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion. Interactive Cardiovascular and Thoracic Surgery, 2013, 16, 263-269.	0.5	28
82	Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines. Clinical Cancer Research, 2013, 19, 3508-3519.	3.2	106
83	Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. Oncology Reports, 2013, 30, 2992-2998.	1.2	11
84	Critical appraisal of the use of regorafenib in the management of colorectal cancer. Cancer Management and Research, 2013, 5, 49.	0.9	5
85	Basic Science of Lung Cancer in Older Patients. , 2013, , 3-12.		0
86	Control of post-thoracotomy pain by transcutaneous electrical nerve stimulation: effect on serum cytokine levels, visual analogue scale, pulmonary function and medication. European Journal of Cardio-thoracic Surgery, 2012, 41, 861-868.	0.6	71
87	Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1830-1844.	0.5	23
88	Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. Expert Opinion on Investigational Drugs, 2012, 21, 949-959.	1.9	21
89	First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial. Journal of Clinical Oncology, 2012, 30, 3002-3011.	0.8	229
90	Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors. PLoS ONE, 2011, 6, e28841.	1.1	40

#	ARTICLE	IF	CITATIONS
91	Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2011, 12, 420-424.	0.5	42
92	Trastuzumab Resistance in Breast Cancer. , 2011, , 51-60.		0
93	Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study. <i>Cancer Investigation</i> , 2010, 28, 820-827.	0.6	18
94	Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells. <i>Clinical Cancer Research</i> , 2010, 16, 4990-5001.	3.2	79
95	Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. <i>Lung Cancer</i> , 2010, 67, 86-92.	0.9	23
96	Resistance mechanisms of tumour cells to EGFR inhibitors. <i>Clinical and Translational Oncology</i> , 2009, 11, 270-275.	1.2	19
97	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 519-527.	12.5	391
98	Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. <i>Journal of Cellular Physiology</i> , 2008, 216, 698-707.	2.0	33
99	The use of xenograft models for the selection of cancer treatments with the EGFR as an example. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 200-211.	2.0	56
100	Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase C β inhibitor, in non-small cell lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1698-1707.	1.9	27
101	Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non-small Cell Lung Cancer Cells to Treatment with Gefitinib. <i>Clinical Cancer Research</i> , 2007, 13, 2795-2803.	3.2	248
102	Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. <i>Expert Opinion on Drug Discovery</i> , 2007, 2, 335-348.	2.5	5
103	Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 117-126.	0.2	0
104	Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 276-283.	0.2	0
105	Combination of Standard Chemotherapy and Targeted Agents. <i>Journal of Thoracic Oncology</i> , 2007, 2, S19-S23.	0.5	2
106	Chronic inflammation and oxidative stress in human carcinogenesis. <i>International Journal of Cancer</i> , 2007, 121, 2381-2386.	2.3	809
107	Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. <i>Differentiation</i> , 2007, 75, 788-799.	1.0	72
108	A Randomized Phase II Study of Pemetrexed or RAD001 as Second-Line Treatment of Advanced Non-small-Cell Lung Cancer in Elderly Patients: Treatment Rationale and Protocol Dynamics. <i>Clinical Lung Cancer</i> , 2007, 8, 568-571.	1.1	18

#	ARTICLE	IF	CITATIONS
109	Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment. Targeted Oncology, 2006, 1, 123-129.	1.7	4
110	Lonafarnib in cancer therapy. Expert Opinion on Investigational Drugs, 2006, 15, 709-719.	1.9	44
111	Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib. Cancer Research, 2006, 66, 10100-10111.	0.4	313
112	Hypoxia-inducible Factor 1 α and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract Cancer. Journal of the National Cancer Institute, 2005, 97, 1272-1286.	3.0	101
113	Resistance to epidermal growth factor receptor-targeted therapy. Drug Resistance Updates, 2005, 8, 298-310.	6.5	84
114	Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer, 2004, 100, 270-278.	2.0	100
115	Elevated Serum Levels of Interleukin-8 in Advanced Non-Small Cell Lung Cancer Patients: Relationship with Prognosis. Journal of Interferon and Cytokine Research, 2002, 22, 1129-1135.	0.5	70
116	Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy?. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.5	0